Last Price Today's Change   Day's Range   Trading Volume
0.04   -0.009 (18.37%)  0.039 - 0.05  58,165,586


Avg Volume (4 weeks):15,148,921
4 Weeks Range:0.039 - 0.06
4 Weeks Price Volatility (%):
52 Weeks Range:0.011 - 0.063
52 Weeks Price Volatility (%):
Average Price Target:-


No recent Headlines for this stock.

Business Background

Patrys Limited is engaged in the commercialization of its technologies to develop natural human antibody-based therapeutic products for the treatment of cancer. The Company is engaged in conducting research and development activities in the biopharmaceutical sector. The Company's products include PAT-SM6, PAT-LM1 and PAT-SC1. PAT-SM6 is a natural human antibody that binds to multiple types of cancer, including solid tumors, such as melanoma, breast, colon and pancreatic, as well as blood-based cancers, such as multiple myeloma. PAT-SM6 has completed its Phase I clinical trials for melanoma and Phase I/IIa clinical trials for multiple myeloma. PAT-LM1 is a natural human antibody that can be used for treatment of multiple types of cancer, with potency against colon, lung, breast, ovary and pancreatic cancers. PAT-LM1 is in pre-clinical stage of its study. It offers 3E10 Deoxymab, a lupus autoantibody. It is toxic to cancer cell that has deficiencies in deoxyribonucleic acid repair.

  Be the first to like this.

I3 Messenger
Individual or Group chat with anyone on I3investor

668  879  643  1803 

Top 10 Active Counters
 88E 0.044+0.003 
 CLE 0.003-0.006 
 ROG 0.01+0.001 
 LPD 0.018+0.003 
 FNT 0.018+0.002 
 PAB 0.04-0.009 
 PKD 0.054+0.017 
 CLZ 0.001-0.001 
 CRO 0.069+0.008 
 AUZ 0.019-0.001